Adocia SA
PAR:ADOC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Adocia SA
Total Liabilities & Equity
Adocia SA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Adocia SA
PAR:ADOC
|
Total Liabilities & Equity
€27.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-10%
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities & Equity
€398.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
4%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities & Equity
€159m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
9%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities & Equity
€179m
|
CAGR 3-Years
16%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Liabilities & Equity
$233.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
Abivax SA
PAR:ABVX
|
Total Liabilities & Equity
€205.2m
|
CAGR 3-Years
40%
|
CAGR 5-Years
24%
|
CAGR 10-Years
10%
|
|
Adocia SA
Glance View
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
See Also
What is Adocia SA's Total Liabilities & Equity?
Total Liabilities & Equity
27.2m
EUR
Based on the financial report for Jun 30, 2025, Adocia SA's Total Liabilities & Equity amounts to 27.2m EUR.
What is Adocia SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-10%
Over the last year, the Total Liabilities & Equity growth was 15%. The average annual Total Liabilities & Equity growth rates for Adocia SA have been -13% over the past three years , -11% over the past five years , and -10% over the past ten years .
